C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual nativecomponents from which they are formed.
Suitable for use in ELISA and Immunohistochemistry. Not suitable for Western Blot. Other applications have not been tested.
Immunohistochemistry: Frozen and paraffin sections
Optimal dilutions to be determined by the researcher.
RPMI 1640 with 10% fetal calf serum
X63.Ag8.653 myeloma cells with spleen cells from Balb/c mice.
Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
|Purified by Protein A affinity chromatography.|
|Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide. |
|Recognizes a neoepitope exposed on human C9 when incorporated into the TCC. Binds both membrane-bound MAC and fluid-phase SC5b-9 complexes. Species Crossreativity: porcine, baboon and equine.|
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|
1. Mollnes TE, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the|
human terminal complement complex in tissue and plasma. Scand J Immunol 22:183-195.
2. Drogari-Aspiranthitou M, Kuijper EJ, Dekker N, Dankert J (2002) Complement activation and formation of the
membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal
activity. Infect Immunol 70:3752-3758.
3. Jansen JH, Høgåsen K, Mollnes TE (1993) Extensive complement activation in hereditary porcine
membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 143:1356-1365.
4. Mollnes TE, Lea T, Frøland SS, Harbroe M (1985) Quantification of the terminal complement complex in human
plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the
complex. Scand J Immunol 22:197-202.
5. Mollnes TE (1997) Analysis of in vivo complement activation. Herzenberg LA, Weir DM, Herzenberg LA, Blackwell
C: Weir's Handbook of Experimental Immunology. Boston, MA: Blackwell Science, pp. 78.1-78.8.